Purple Biotech Overview
- Year Founded
-
1968
- Status
-
Public
- Employees
-
10
- Stock Symbol
-
PPBT-L
- Investments
-
4
Purple Biotech General Information
Description
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
Contact Information
Website
www.purple-biotech.comCorporate Office
- 4 Oppenheimer Street
- Science Park
- Rehovot 7670104
- Israel
Corporate Office
- 4 Oppenheimer Street
- Science Park
- Rehovot 7670104
- Israel
Purple Biotech Timeline
Purple Biotech Stock Performance
As of 20-Oct-2026, Purple Biotech’s current market cap is $10.5M with 3.25B shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.5M | 3.25B | 94.9K | -$0.10 |
Purple Biotech Financials Summary
As of 30-Jun-2026, Purple Biotech has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (437) | (3,775) | 4,921 | 5,618 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (24,502) | (26,477) | (7,312) | (20,198) |
| Net Income | (24,493) | (26,386) | (7,240) | (19,880) |
| Total Assets | 14,166 | 17,572 | 37,038 | 44,302 |
| Total Debt | 134 | 244 | 183 | 351 |
Purple Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Purple Biotech Comparisons
Industry
Financing
Details
Purple Biotech Competitors (5)
One of Purple Biotech’s 5 competitors is BioInvent International, a Formerly VC-backed company based in Lund, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioInvent International | Formerly VC-backed | Lund, Sweden | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Zentalis Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Seagen | Formerly VC-backed | Bothell, WA |
Purple Biotech Patents
Purple Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2019008583-A1 | Celecoxib and amlodipine formulation and method of making the same | Inactive | 06-Jul-2017 | ||
| WO-2011100659-A2 | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs | Inactive | 12-Feb-2010 | ||
| WO-2011100659-A3 | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs | Inactive | 12-Feb-2010 | ||
| US-20110136793-A1 | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs | Active | 28-May-2008 | ||
| US-20160058744-A1 | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs | Active | 28-May-2008 | A61K31/4422 |
Purple Biotech Signals
Purple Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Purple Biotech Investments & Acquisitions (4)
Purple Biotech’s most recent deal was a Merger/Acquisition with Immunorizon. The deal was made on 15-Feb-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Immunorizon | 15-Feb-2023 | Merger/Acquisition | Other Healthcare Technology Systems | ||
| FameWave | 08-Jan-2020 | Merger/Acquisition | Drug Discovery | ||
| TyrNovo | 06-Oct-2017 | Secondary Transaction - Private | Drug Discovery | ||
| TyrNovo | 06-Oct-2017 | Merger/Acquisition | Drug Discovery |
Purple Biotech ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Purple Biotech Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| TyrNovo | Herzliya, Israel | 2005 |
Purple Biotech FAQs
-
When was Purple Biotech founded?
Purple Biotech was founded in 1968.
-
Where is Purple Biotech headquartered?
Purple Biotech is headquartered in Rehovot, Israel.
-
What is the size of Purple Biotech?
Purple Biotech has 10 total employees.
-
What industry is Purple Biotech in?
Purple Biotech’s primary industry is Drug Discovery.
-
Is Purple Biotech a private or public company?
Purple Biotech is a Public company.
-
What is Purple Biotech’s stock symbol?
The ticker symbol for Purple Biotech is PPBT-L.
-
What is the current market cap of Purple Biotech?
The current market capitalization of Purple Biotech is $10.5M.
-
Who are Purple Biotech’s competitors?
BioInvent International, Ayala Pharmaceuticals, Astellas Pharma, Zentalis Pharmaceuticals, and Seagen are competitors of Purple Biotech.
-
What is Purple Biotech’s annual earnings per share (EPS)?
Purple Biotech’s EPS for 12 months was -$0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process